Breast Cancer Herceptin Treatment Shows Impressive Results
Continuing Herceptin treatment prevents breast cancer progression in women with aggressive metastatic breast cancer. Women with HER2-positive breast cancer benefit from nearly three extra months of life without progression.
New data presented at the American Society for Clinical Oncology Annual Meeting (ASCO) demonstrate that Herceptin helps women with advanced (metastatic) HER2-positive breast cancer live longer without their cancer progressing. The final analysis of the randomized phase III GBG-26 study showed that Herceptin continued to work in women who needed additional treatment after their cancer progressed during previous Herceptin treatment.
Herceptin and Breast Cancer Treatment
Herceptin plus Xeloda prolonged survival without progression of the cancer by nearly 3 months compared to chemotherapy alone (Time to progression from 5.6 to 8.2 months).
Full Story: Breast Cancer Herceptin Treatment Shows Impressive Results